Introduction
Hepatocellular carcinoma (HCC), largely attributable to chronic hepatitis B virus (HBV) infection, is 2 the second most common gastrointestinal solid tumors and remains the second leading cause of 3 cancer-related death in China 1 . The high mortality of HCC is due partly to the fact that early-stage HCC 4 shows no obvious symptoms and the diagnostic accuracy of AFP (alpha-fetoprotein, a serum biomarker for 5 the diagnosis of HCC in clinical use) is unsatisfactory. The sensitivity and specificity of high serum AFP for 6 HCC were reported to range from 39-64% and 76-91%, respectively. 2-4 Therefore, a novel biomarker for 7 the detection of HCC, especially early-stage HCC, need to be identified. 8 Circular RNAs (termed circRNAs) are covalently closed, single-stranded and stable transcripts. 5 In our 9 previous study, we demonstrated that circRNA expression profiles in HCC and adjacent nontumor liver 10 tissues are significantly different and circular RNA cSMARCA5 inhibits the growth and metastasis of 11 HCC. 6 Furthermore, it has been reported that plasma circRNAs are enriched, stable and can be biomarkers 12 for non-small cell lung cancer and systemic lupus erythematosus 7 . In this study, using microarray and 13 qRT-PCR (quantitative real-time polymerase chain reaction), we tried to explore whether plasma circRNAs 14 can be biomarkers to diagnose HBV-related HCC (referred to below as HCC). The study design is listed in Figure 1 . In total, 1195 plasma samples, 40 paired HCC and adjacent 3 noncancerous liver (ANL) tissues were collected from three hospitals in China. The recruited participants 4 were defined as healthy individuals, patients with chronic hepatitis B (CHB), patients with HBV-related 5 liver cirrhosis (referred to below as liver cirrhosis), or patients with HCC by medical doctors, according to 6 eligibility criteria listed in Supplementary Table 1 . Supplementary Table 2 . In addition, for the 40 HCC patients undergoing 14 hepatectomy in the training set, we also collected their plasma at the 30th day after hepatectomy, their HCC 15 and paired ANL tissues. The details of the clinicopathological characteristics of these 40 HCC patients are 16 listed in Supplementary Table 3 .
17
Human specimen collection was approved by the ethics committee of each hospital. Written informed 18 consent was obtained from each patient according to the policies of the committee.
19

RNA Isolation
20
For the HCC cell lines and the HCC and ANL tissues, the total RNA was extracted using RNAiso Plus 21 (Takara, Code No. 9109) according to the manufacturer's instructions. 22 For the plasma, the total RNA was extracted using the TRIzol™ LS Reagent (ThermoFisher, Code No. The total RNAs extracted from the plasma of five HCC patients and five CHB patients were used for 5 microarray analysis as described previously. 8, 9 In brief, the RNAs were digested, amplificated, labelled and 6 hybridized onto the microarray (CapitalBio Technology Human CircRNA Array, Version 2.0). Differential 7 expression analysis of circRNAs was performed using GeneSpring software V13.0 (Agilent). We used 8 threshold values of ≥ 2 or ≤− 2-fold change and a t-test P-value < 0.05. The differentially expressed 9 circRNAs are listed in Supplementary Table 4 . The data were Log2 transformed and median centered by 10 genes using the Adjust Data function of CLUSTER 3.0 software and were then further analyzed by 11 hierarchical clustering with average linkage. 10 Finally, we performed tree visualization by using Java Supplementary Table 5 . The primers for the 21 circRNAs were divergent and circRNA specific. (Supplementary Figure 1A ) 22 For the HCC and ANL tissues, ACTB was employed as the endogenous control, and the relative 23 10 expression was calculated using the comparative ΔΔCt method. 1 Since there is no accepted endogenous control for the quantitation of mRNAs/circRNAs in plasma, we 2 used absolute quantitation when detecting the expression of the candidate circRNAs in the plasma as 3 previously described. [11] [12] [13] Briefly, the PCR products were amplified from human pooled plasma cDNA using 4 the primers of the four candidate circRNAs, respectively. Subsequently, the four PCR products were cloned 5 into pUC57 vector, respectively. The resulting constructs were verified by direct sequencing and serially 6 diluted from 5×10 7 copies/μl to 5 copies/μl, respectively. Those diluted constructs were run in parallel with was considered to be statistically significant when P<0.05.
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The remaining methods are described in the Supplementary Data 1. 
Identification of Circular RNAs By Microarray and PCR in Human Plasma Samples 2
Using circRNA microarray, we compared the expression of circular RNAs in the plasma from five 3 HCC patients and five CHB patients (discovery set). Among the 371 differentially expressed circRNAs, 326 4 were upregulated and 45 were downregulated in the plasma from HCC patients compared with that from 5 CHB patients ( Supplementary Table 4 , Supplementary Figure 2A ). We hypothesized that circRNAs in HCC 6 tissues could be secreted into plasma. By overlapping the 326 upregulated plasma circRNAs and the 6584 7 circRNAs detected in HCC tissues from our group's previous study 6 , we obtained 10 candidate circRNAs 8 ( Supplementary Table 4 ). Subsequently, we successfully validated four of these (hsa_circ_0000976, Figure 4) and by qRT-PCR using circRNA-specific divergent primers, agarose gel 12 electrophoresis and Sanger sequencing. Furthermore, we found that incubating plasma at room temperature 13 for up to 24 h had minimal effect on the expression of these four circRNAs ( Supplementary Figure 2E) , 14 indicating that they were stable in plasma and could be used as a biomarker. In addition, after the treatment 15 with RNase R (a highly processive 3'-to-5' exoribonuclease that digests linear RNAs 18 ), none showed 16 significant changes (Supplementary Figure 3D) , which demonstrated that they were truly circular and not 6) showed that these four circRNAs existed in the plasma from the mice in the HepG2 and Huh7 groups but 23 13 not in the control group. This proved that HCC cells secrete circRNAs into plasma. (Figure 1) and found that the expression of hsa_circ_0000976, 5 hsa_circ_0007750 and hsa_circ_0139897 (but not hsa_circ_0003506) in the plasma from the HCC patients 6 was higher than that in the plasma from the healthy controls, CHB patients and liver cirrhosis patients 7 (Supplementary Figure 7A ). For the 40 HCC patients undergoing hepatectomy in the training set, we also 8 detected the expression of these four circRNAs in their plasma at the 30th day after hepatectomy and in their 9 HCC and paired ANL tissues. We found that the expression of hsa_circ_0000976, hsa_circ_0007750 and 10 hsa_circ_0139897 (but not hsa_circ_0003506) in the plasma from the HCC patients was positively 11 correlated with the expression in their HCC tissues (Supplementary Figure 7B) and was significantly 12 downregulated after hepatectomy (Supplementary Figure 7C) . Furthermore, the expression of 13 hsa_circ_0000976 and hsa_circ_0007750 was higher in the HCC tissues than in the ANL tissues 14 (Supplementary Figure 7D) . Therefore, we chose hsa_circ_0000976, hsa_circ_0007750 and 15 hsa_circ_0139897 as the candidate circRNAs for the diagnosis of HCC.
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Using Cutoff Finder 14 (http://molpath.charite.de/cutoff/), we determined that the best cutoff values of 17 plasma hsa_circ_0000976, hsa_circ_0007750 and hsa_circ_0139897 for distinguishing HCC and Non-HCC 18 (healthy controls, CHB patients and liver cirrhosis patients as a whole) were 1067, 4324 and 1108 copies/ml 19 of plasma, respectively. Their diagnostic performance is shown in Supplementary Table 6 . To improve 20 diagnostic accuracy, using binary logistic regression, we built the diagnostic model CircPanel. The predicted 21 probability of being detected as HCC by the CircPanel was calculated by: Logit (P＝HCC)＝
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-3.502+1.920*hsa_circ_0000976+2.800*hsa_circ_0007750+3.154*hsa_circ_0139897. In this equation, the 23 14 circRNA symbol was substituted with the discretized value one when the level of the circRNA was higher 1 than the corresponding best cutoff value; otherwise, it was substituted with the discretized value of zero. If 2 the result of logit[p=HCC] was higher than 0.5, then the detected sample was predicted as HCC; otherwise it 3 was Non-HCC. As expected, the diagnostic accuracy of the CircPanel was higher than those of Table 6 ). 7 We also analyzed the diagnostic performance of AFP, whose recommended clinical cutoff is 20 ng/ml, 8 in detecting HCC in the training set (Table 1 ). Furthermore, using the aforementioned method, we combined 9 the CircPanel and AFP (CircPanel+AFP) to diagnosis HCC. The predicted probability of being detected as 10 HCC by CircPanel+AFP was calculated as Logit (P＝HCC)＝-2.152+3.321*CircPanel+2.241*AFP. The 11 diagnostic performance of CircPanel+AFP was then analyzed (Table 1) .
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The Performance of CircPanel, AFP and Their Combination for the Diagnosis of HCC 13 We then detected the expression of hsa_circ_0000976, hsa_circ_0007750 and hsa_circ_0139897 in the As a result, we found that both the CircPanel and CircPanel+AFP showed a higher accuracy than AFP Healthy, Small-HCC versus CHB and Small-HCC versus Cirrhosis. Similar results were obtained, especially 21 in Small-HCC versus CHB and Small-HCC versus Cirrhosis (Table 2, Figure 3 ).
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The Performance of CircPanel for the Diagnosis of AFP-negative HCC and AFP-negative Small-HCC 23 
